Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.
暂无分享,去创建一个
David C. Smith | T. Choueiri | M. Atkins | C. Drake | M. Sznol | H. Kluger | J. Wigginton | A. Gupta | G. Kollia | D. McDermott | J. Powderly | A. Gutierrez | V. Sankar